-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 4, 2025

Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Experts discuss innovations and advancements in bispecific antibodies that could transform their use in the next 5 years.

Video content above is prompted by the following:

What innovations or advancements in bispecific antibodies could transform their use in the next 5 years?


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.